

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of reducing the accumulation of globotriaosylceramide in a subject diagnosed as having Fabry disease comprising:
 - a) administering to the subject ~~a viral or non-viral~~ **an adeno-associated virus (AAV)** vector encoding a α -galactosidase A, **wherein the administration of the vector results in targeting of the α -galactosidase A to the liver** and
 - b) subsequently administering to the subject a therapeutically effective amount of an exogenously produced natural or recombinant α -galactosidase A, such that the accumulation of globotriaosylceramide in the subject is reduced.
- 2-5. (Canceled)
6. (Previously presented) The method according to claim 1 wherein the α -galactosidase A is a recombinant α -galactosidase A.
- 7-16. (Canceled)
17. (Previously presented) The method of claim 1, wherein the exogenously produced natural or recombinant α -galactosidase is administered intravenously.
18. (Previously presented) The method of claim 1, wherein the viral or non-viral vector encoding a α -galactosidase A is administered ex vivo.
19. (Previously presented) The method of claim 1, wherein the viral or non-viral vector encoding a α -galactosidase A is administered in vivo.